Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Director departure
Appointed director
ORAMED PHARMACEUTICALS INC. (ORMP) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financi...
Docs: "SECURITIES PURCHASE AGREEMENT",
"EXECUTION VERSION",
"WARRANT NO. ORMP CS-1 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"WARRANT NO. ORMP CS-2 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"WARRANT NO. ORMP CS-3 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"WARRANT NO. ORMP CS-4 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"WARRANT NO. ORMP CS-5 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"Scilex Holding Company Specimen Warrant Certificate",
"Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement.",
"Subsidiary Guarantee, by and among Oramed Pharmaceuticals, Acquiom Agency Services LLC, Scilex Holding Company, and certain subsidiaries of Scilex Holding Company party thereto"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Acquisition/merger/asset purchase announced
Docs: "STOCK PURCHASE AGREEMENT",
"SENIOR SECURED, SUPER-PRIORITY DEBTOR-IN-POSSESSION"
08/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Stalking Horse Stock Purchase Term Sheet This term sheet sets forth the principal terms of a proposed equity sale transaction between the parties described herein. Consummation of the Sale is subject to final definitive documentation to be negotiated in good faith between the parties, the satisfaction or waiver of the Closing Conditions set forth below, and authorization and approval by the United States Bankruptcy Court for the Southern District of Texas . This Stalking Horse Term Sheet is solely for discussion purposes and does not purport to summarize all of the terms, conditions, covenants, representations, warranties and other provisions which would be contained in the definitive documentation for the transactions described herein. Seller Sorrento Therapeutics, Inc. Purchaser Oramed P..."
07/13/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/31/2023 ARS Form ARS - Annual Report to Security Holders:
05/31/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/31/2023 4 KIDRON NADAV (President and CEO) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.
Txns: Granted 120,000 shares @ $0
05/31/2023 4 Kidron Miriam (Chief Scientific Officer) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.
Txns: Granted 53,500 shares @ $0
05/31/2023 4 Derovan Netanel (Chief Legal Officer) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.
Txns: Granted 20,500 shares @ $0
05/31/2023 4 Hexter Joshua (COO & CBO) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.
Txns: Granted 27,000 shares @ $0
05/31/2023 4 Silberman David (CFO) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.
Txns: Granted 24,500 shares @ $0
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/01/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/01/2023 3 Shapiro Benjamin (Director) has filed a Form 3 on ORAMED PHARMACEUTICALS INC.
05/01/2023 8-K Quarterly results
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/04/2023 4 Mayer Arie (Director) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.
Txns: Bought 5,009 shares @ $2.22, valued at $11.1k
Bought 3,800 shares @ $2.21, valued at $8.4k
03/16/2023 4 KIDRON NADAV (President and CEO) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.
Txns: Bought 26,000 shares @ $2.039, valued at $53k
03/15/2023 4 KIDRON NADAV (President and CEO) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.
Txns: Bought 100,000 shares @ $2.01, valued at $201k
03/15/2023 4 Kidron Miriam (Chief Scientific Officer) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.
Txns: Sold 100,000 shares @ $2.01, valued at $201k
03/15/2023 4 Rozov Yadin (Director) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.
Txns: Bought 20,000 shares @ $1.956, valued at $39.1k
Bought 50,000 shares @ $2.049, valued at $102.5k
03/06/2023 10-K Annual Report for the period ended December 31, 2022
02/27/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "FOURTH AMENDED AND RESTATED BY-LAWS, ADOPTED EFFECTIVE FEBRUARY 23, 2023",
"ARTICLE XVI 11. The Corporation’ s obligation, if any, to indemnify or to advance expenses to any person serving at its request as a director or officer of another corporation, partnership, joint venture, trust or other enterprise shall be reduced by any amount such person may collect as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust or other enterprise. 16 ARTICLE XIV FORUM SELECTION 1. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery and any appellate court thereof shall be the sole and exclusive forum for any derivative action, suit, or proceeding brought on behalf of the Corporation, any action, suit, or proceeding asserting a claim of breach of fiduciary duty owed by an..."
01/04/2023 4 Rabinowitz Michael (Chief Commercial Officer) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.
Txns: Sold 1,425 shares @ $13.0132, valued at $18.5k
Sold 11,900 shares @ $12.4917, valued at $148.7k
12/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "INVESTOR PRESENTATION DATED DECEMBER 12, 2022"
11/14/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy